Literature DB >> 2929999

Pharmacokinetics of intravenous dantrolene in children.

J Lerman1, M E McLeod, H A Strong.   

Abstract

To determine the pharmacokinetics of iv dantrolene and its metabolites in children, ten children 2-7 yr of age scheduled for minor elective surgery, were studied. After induction of anesthesia and tracheal intubation, dantrolene (2.4 mg/kg) was administered iv over 10.2 +/- 0.83 min. Venous blood samples (3 ml) were obtained 1, 5, 10, 20, and 30 min and 1, 2, 4, 8, 12, and 20 h after the dantrolene infusion. Whole blood concentrations of dantrolene, 5-hydroxydantrolene, and nitroreduced acetylated dantrolene were measured by high-performance liquid chromatography. The whole blood concentration of dantrolene decreased rapidly from a mean (+/- SD) of 6.03 +/- 0.93 microgram/ml 1 min after the end of the dantrolene infusion to 3.56 +/- 0.49 microgram/ml at 1 h. Between 1 and 4 h, the concentration of dantrolene either remained constant or increased slightly. Thereafter, the concentration of dantrolene decreased slowly with an elimination half-life (mean +/- SD) of 10.0 +/- 2.6 h. The mean (+/- SD) time for the concentration of dantrolene to decrease to 3.0 micrograms/ml was 6.55 +/- 2.88 h. The whole blood concentration of 5-hydroxydantrolene reached a maximum of 0.60 +/- 0.18 microgram/ml approximately 7 h after the dantrolene and decreased thereafter with an elimination half-life of 9.0 +/- 2.5 h. The concentration of nitroreduced acetylated dantrolene was below the limit for detection at all times. All children recovered without complications. Intravenous dantrolene, 2.4 mg/kg, produces safe and predictable blood concentrations in children similar to those reported in adults.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2929999     DOI: 10.1097/00000542-198904000-00013

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  4 in total

1.  Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States.

Authors:  Barbara W Brandom; Marilyn Green Larach; Min-Shue Alvin Chen; Michael C Young
Journal:  Anesth Analg       Date:  2011-03-03       Impact factor: 5.108

2.  Educational computer simulation of malignant hyperthermia.

Authors:  H A Schwid; D O'Donnell
Journal:  J Clin Monit       Date:  1992-07

3.  Pharmacokinetics of Dantrolene in the Plasma Exchange Treatment of Malignant Hyperthermia in a 14-Year-Old Chinese Boy: A Case Report and Literature Review.

Authors:  Xiaoxiao Li; Chao Li; Yang Zhou; Zhengqian Li; Xin Xiong; Chuhui Wang; Congya Zhou; Bin Han; Li Yang; Xiangyang Guo
Journal:  Front Med (Lausanne)       Date:  2022-08-12

4.  A novel RyR1-selective inhibitor prevents and rescues sudden death in mouse models of malignant hyperthermia and heat stroke.

Authors:  Toshiko Yamazawa; Takuya Kobayashi; Nagomi Kurebayashi; Masato Konishi; Satoru Noguchi; Takayoshi Inoue; Yukiko U Inoue; Ichizo Nishino; Shuichi Mori; Hiroto Iinuma; Noriaki Manaka; Hiroyuki Kagechika; Arkady Uryash; Jose Adams; Jose R Lopez; Xiaochen Liu; Christine Diggle; Paul D Allen; Sho Kakizawa; Keigo Ikeda; Bangzhong Lin; Yui Ikemi; Kazuto Nunomura; Shinsaku Nakagawa; Takashi Sakurai; Takashi Murayama
Journal:  Nat Commun       Date:  2021-07-13       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.